{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:16:35Z","timestamp":1719879395216},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,1]]},"DOI":"10.7759\/cureus.63563","type":"journal-article","created":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T09:16:13Z","timestamp":1719825373000},"source":"Crossref","is-referenced-by-count":0,"title":["An Unusual Increase in the CD38 Marker Observed in a Multiple Myeloma Patient With t(11;14) Translocation: A Case Report"],"prefix":"10.7759","author":[{"given":"Felix","family":"Rivera Troia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando J","family":"Ocasio Villa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma","volume":"111","author":"Kyle RA","year":"2008","unstructured":"Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008, 111:2962-72. 10.1182\/blood-2007-10-078022","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.59781","article-title":"Multiple myeloma: a personal account of my journey with the disease and response to teclistamab","volume":"16","author":"Ahmad M","year":"2024","unstructured":"Ahmad M, Zahrani MF, Alotaibi GS, et al.. Multiple myeloma: a personal account of my journey with the disease and response to teclistamab. Cureus. 2024, 16:e59781. 10.7759\/cureus.59781","journal-title":"Cureus"},{"key":"ref3","unstructured":"American Cancer Society. risk factors for multiple myeloma. (2024). Accessed: June 17, 2024: https:\/\/pubmed.ncbi.nlm.nih.gov\/18332230\/."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2019.07.001","article-title":"Integrated analysis of TP53 gene and pathway alterations in The Cancer Genome Atlas","volume":"28","author":"Donehower LA","year":"2019","unstructured":"Donehower LA, Soussi T, Korkut A, et al.. Integrated analysis of TP53 gene and pathway alterations in The Cancer Genome Atlas. Cell Rep. 2019, 28:1370-84. 10.1016\/j.celrep.2019.07.001","journal-title":"Cell Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018028530","article-title":"Impact of acquired del(17p) in multiple myeloma","volume":"3","author":"Lakshman A","year":"2019","unstructured":"Lakshman A, Painuly U, Rajkumar SV, et al.. Impact of acquired del(17p) in multiple myeloma. Blood Adv. 2019, 3:1930-8. 10.1182\/bloodadvances.2018028530","journal-title":"Blood Adv"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15245829","article-title":"The role of t(11;14) in tailoring treatment decisions in multiple myeloma","volume":"15","author":"Kleber M","year":"2023","unstructured":"Kleber M, Ntanasis-Stathopoulos I, Terpos E. The role of t(11;14) in tailoring treatment decisions in multiple myeloma. Cancers (Basel). 2023, 15:42-4. 10.3390\/cancers15245829","journal-title":"Cancers (Basel)"},{"key":"ref7","article-title":"Multiple myeloma with t(11;14): unique biology and evolving landscape","volume":"12","author":"Bal S","year":"2022","unstructured":"Bal S, Kumar SK, Fonseca R, Gay F, Hungria VT, Dogan A, Costa LJ. Multiple myeloma with t(11;14): unique biology and evolving landscape. Am J Cancer Res. 2022, 12:2950-65.","journal-title":"Am J Cancer Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21252","article-title":"Understanding biology to tackle the disease: multiple myeloma from bench to bedside, and back","volume":"64","author":"Bianchi G","year":"2014","unstructured":"Bianchi G, Anderson KC. Understanding biology to tackle the disease: multiple myeloma from bench to bedside, and back. CA Cancer J Clin. 2014, 64:422-44. 10.3322\/caac.21252","journal-title":"CA Cancer J Clin"},{"key":"ref9","unstructured":"Effective Health Care (EHC) program. serum-free light chain analysis for the diagnosis, management, and prognosis of plasma cell dyscrasias. (2022). Accessed: June 29, 2024: https:\/\/effectivehealthcare.ahrq.gov\/products\/plasma-cell-dyscrasias-sflc-assay\/research-protocol."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2010.06.012","article-title":"The cytokine\/chemokine pattern in the bone marrow environment of multiple myeloma patients","volume":"38","author":"Cao Y","year":"2010","unstructured":"Cao Y, Luetkens T, Kobold S, et al.. The cytokine\/chemokine pattern in the bone marrow environment of multiple myeloma patients. Exp Hematol. 2010, 38:860-7. 10.1016\/j.exphem.2010.06.012","journal-title":"Exp Hematol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.31557\/APJCP.2022.23.9.2937","article-title":"Serum levels of interleukin-1\u03b2 and disease progression in multiple myeloma patients: a case and control study","volume":"23","author":"Teimuri Nobari S","year":"2022","unstructured":"Teimuri Nobari S, Rasmi Y, Khadem Ansari MH. Serum levels of interleukin-1\u03b2 and disease progression in multiple myeloma patients: a case and control study. Asian Pac J Cancer Prev. 2022, 23:2937-42. 10.31557\/APJCP.2022.23.9.2937","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/149185","article-title":"Chronic inflammation and cytokines in the tumor microenvironment","volume":"2014","author":"Landskron G","year":"2014","unstructured":"Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014, 2014:149185. 10.1155\/2014\/149185","journal-title":"J Immunol Res"},{"key":"ref13","unstructured":"What is kidney failure. (2024). Accessed. June 29, 2024: https:\/\/www.myeloma.org\/what-is-kidney-failure."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/life12060812","article-title":"Review of multiple myeloma genetics including effects on prognosis, response to treatment, and diagnostic workup","volume":"12","author":"Wiedmeier-Nutor JE","year":"2022","unstructured":"Wiedmeier-Nutor JE, Bergsagel PL. Review of multiple myeloma genetics including effects on prognosis, response to treatment, and diagnostic workup. Life (Basel). 2022, 12:4-6. 10.3390\/life12060812","journal-title":"Life (Basel)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/15330338211065252","article-title":"The prognostic role of cyclin D1 in multiple myeloma: a systematic review and meta-analysis","volume":"21","author":"Jiang Y","year":"2022","unstructured":"Jiang Y, Zhang C, Lu L, et al.. The prognostic role of cyclin D1 in multiple myeloma: a systematic review and meta-analysis. Technol Cancer Res Treat. 2022, 21:15330338211065252. 10.1177\/15330338211065252","journal-title":"Technol Cancer Res Treat"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-471888","article-title":"Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells","volume":"121","author":"Walker BA","year":"2013","unstructured":"Walker BA, Wardell CP, Johnson DC, et al.. Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. Blood. 2013, 121:3413-9. 10.1182\/blood-2012-12-471888","journal-title":"Blood"},{"key":"ref17","unstructured":"Role of CD38 antibodies in multiple myeloma. (2022). Accessed. June 29, 2024: https:\/\/www.targetedonc.com\/view\/role-of-cd38-antibodies-in-multiple-myeloma."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15073","article-title":"Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence","volume":"112","author":"Kitadate A","year":"2021","unstructured":"Kitadate A, Terao T, Narita K, et al.. Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence. Cancer Sci. 2021, 112:3645-54. 10.1111\/cas.15073","journal-title":"Cancer Sci"},{"key":"ref19","unstructured":"Daratumumab. uses, interactions, mechanism of action. (2023). Accessed: June 29, 2024: https:\/\/go.drugbank.com\/drugs\/DB09331."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0283-0","article-title":"Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma","volume":"9","author":"Sanchez L","year":"2016","unstructured":"Sanchez L, Wang Y, Siegel DS, Wang ML. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. J Hematol Oncol. 2016, 9:51. 10.1186\/s13045-016-0283-0","journal-title":"J Hematol Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/265274-an-unusual-increase-in-the-cd38-marker-observed-in-a-multiple-myeloma-patient-with-t1114-translocation-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T09:16:19Z","timestamp":1719825379000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/265274-an-unusual-increase-in-the-cd38-marker-observed-in-a-multiple-myeloma-patient-with-t1114-translocation-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.63563","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,1]]}}}